Ozempic vs Trulicity (semaglutide vs dulaglutide)

Which is better, semaglutide or dulaglutide?

Semaglutide wins on direct evidence (SUSTAIN 7), on breadth of label (obesity, cardiovascular risk in obesity, MASH, kidney disease, plus an oral form), and on weight loss. Dulaglutide remains a sound diabetes-only choice with a large, long cardiovascular outcomes trial, a single-use pen many patients find simple, and approval in children 10 and older, so coverage and indication usually decide in practice. Both are FDA approved and neither is available as a routine compounded product. [1] [2] [5] [7] [8]

How do semaglutide and dulaglutide compare?

Semaglutide and Dulaglutide compared by dimension
Dimension	SemaglutideFavored	Dulaglutide
Head-to-head evidence [1] [3]	SUSTAIN 7: HbA1c down 1.5 points (0.5 mg) and 1.8 points (1.0 mg); weight down 4.6 kg and 6.5 kg at 40 weeks.	SUSTAIN 7: HbA1c down 1.1 points (0.75 mg) and 1.4 points (1.5 mg); weight down 2.3 kg and 3.0 kg at 40 weeks.
Note: SUSTAIN 7 randomized 1,201 adults with type 2 diabetes on metformin. Dulaglutide's later 3.0 and 4.5 mg doses (AWARD-11) were not part of this trial.
Mechanism [7] [8]	Acylated GLP-1 analog that binds albumin; half life about one week.	Two GLP-1 analog chains fused to an IgG4 Fc fragment; half life about 5 days; a much larger molecule with the same receptor target.
FDA labeled indications [7] [8]	Ozempic: type 2 diabetes, cardiovascular risk reduction, chronic kidney disease in type 2 diabetes. Wegovy: chronic weight management, cardiovascular risk reduction in obesity, MASH. Rybelsus: oral, type 2 diabetes.	Trulicity: type 2 diabetes in adults and children 10 and older, and reduction of major adverse cardiovascular events in type 2 diabetes. No weight management indication.
Cardiovascular outcomes [2] [4] [5]	SUSTAIN-6: hazard ratio 0.74 in type 2 diabetes (3,297 adults, median 2.1 years). SELECT: hazard ratio 0.80 in obesity without diabetes (17,604 adults).	REWIND: hazard ratio 0.88 in 9,901 adults with type 2 diabetes over a median 5.4 years, most without prior cardiovascular disease. No trial in people without diabetes.
Weight loss [3] [6]	14.9% vs 2.4% placebo at 68 weeks with 2.4 mg in STEP 1.	Roughly 3 to 5 kg in type 2 diabetes trials; the 4.5 mg dose lost more than the 1.5 mg dose in AWARD-11. No dedicated obesity trial.
Route and dosing [7] [8]	Subcutaneous injection once weekly (Ozempic 0.25 mg escalating to 0.5, 1, or 2 mg; Wegovy to 2.4 mg) or oral tablet once daily (Rybelsus).	Subcutaneous injection once weekly from a single-use pen: 0.75 mg, then 1.5, 3.0, and 4.5 mg at 4-week minimum steps. No oral form.
Common side effects [2] [7] [8]	Nausea, diarrhea, vomiting, constipation, highest during escalation; boxed thyroid C-cell warning.	Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dose dependent and fading with continued use; gastrointestinal events were the main reason for stopping in REWIND; boxed thyroid C-cell warning.
Regulatory and compounding status [8] [9] [12] [13]	FDA approved (2017, 2019, 2021). Shortage-based compounding ended in spring 2025; no generic.	FDA approved (Trulicity 2014). FDA listed dulaglutide injection as in shortage in its October 2024 to February 2025 GLP-1 updates, with all presentations available; it is not listed in FDA's shortage database as of September 27, 2026. Not in a bulk form suitable for compounding; no generic.
Typical cost [7] [8] [10] [11]	Ozempic list price about 998 USD per month; Wegovy about 1,349 USD; 0 to 25 USD with commercial coverage and a savings card.	Trulicity list price 1,006.93 USD per month (from 389 USD self-pay through the manufacturer pharmacy) at any strength; often 25 USD with commercial coverage and a savings card; Medicare Part D covers it for diabetes.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Semaglutide and Dulaglutide: grade, status, and cost
Attribute	Semaglutide	Dulaglutide
Class	GLP-1 receptor agonist (31 amino acid analog of human GLP-1, acylated for once weekly dosing)	GLP-1 receptor agonist (two modified GLP-1 analogs fused to a human IgG4 Fc fragment, once weekly)
What it is	FDA approved GLP-1 agonist with about 15% average weight loss in a 68 week RCT and proven cardiovascular benefit.	FDA approved weekly GLP-1 drug for type 2 diabetes that cut heart attacks, strokes, and heart deaths by 12% over 5.4 years in REWIND; not for weight loss.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: FDA approved
Compounding	FDA approved products (Ozempic 2017, Rybelsus 2019, Wegovy 2021). FDA removed semaglutide from the drug shortage list on February 21, 2025; compounding by 503A pharmacies had to stop by April 22, 2025 and by 503B outsourcing facilities by May 22, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit GLP-1 products and salt forms (semaglutide sodium, semaglutide acetate) that are not the approved active ingredient. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.	FDA approved product (Trulicity, September 2014; 3.0 mg and 4.5 mg doses added in 2020; pediatric indication in 2022; cardiovascular risk reduction indication based on REWIND). Because dulaglutide is a component of an approved drug, 503A pharmacies may compound it only for a documented patient specific need and may not produce essentially a copy of the commercial product. Dulaglutide is not available in a bulk powder form suitable for compounding. FDA listed dulaglutide injection as in shortage in its October 2024 to February 2025 GLP-1 updates, with all presentations available; it is not listed in FDA's shortage database as of September 27, 2026.
WADA	WADA: Not WADA prohibited	WADA: Not WADA prohibited
Routes	Subcutaneous injection once weekly (Ozempic, Wegovy), Oral tablet once daily (Wegovy tablets, Ozempic tablets, Rybelsus)	Subcutaneous injection once weekly (single dose pen)
Typical cost	Manufacturer list price is 1,349.02 USD per month for Wegovy and 1,027.51 USD for Ozempic (checked 2026-09-22), falling to 675 USD for both on January 1, 2027. Manufacturer self-pay prices run 149 to 499 USD per month by product and dose, with the Wegovy pen at 349 USD. With commercial insurance the manufacturer savings offer can bring a covered prescription to 25 USD per month, and eligible Medicare Part D enrollees pay 50 USD per month for Wegovy under the Medicare GLP-1 Bridge (July 2026 to December 2027). A 2024 study found compounded semaglutide at a median 231 USD for the first month during the shortage; compounding is now limited to patient specific needs.	Trulicity list price is 1,006.93 USD per month for four pens at any strength; the manufacturer's self-pay pharmacy sells it from 389 USD per month. With commercial insurance and a manufacturer savings card a covered prescription is often 25 USD per month. Medicare Part D covers it for type 2 diabetes. No generic is available as of the last verified date.
Last verified	Sep 27, 2026	Sep 27, 2026

Has semaglutide been tested directly against dulaglutide?

Direct comparisons of Semaglutide and Dulaglutide
Study	Design and population	Outcome	Grade
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7)2018 PMID 29397376	Phase 3b randomized, open-label, parallel-group trial, 40 weeksn = 1,201 Adults with type 2 diabetes inadequately controlled on metformin	HbA1c reduction 1.5 and 1.8 points with semaglutide 0.5 and 1.0 mg vs 1.1 and 1.4 with dulaglutide 0.75 and 1.5 mg; weight loss 4.6 and 6.5 kg vs 2.3 and 3.0 kg	Evidence: Human RCT evidence

What do semaglutide and dulaglutide cost?

Typical cost of Semaglutide and Dulaglutide
Dimension	Semaglutide	Dulaglutide
Typical cost	$149 to $1,349 per month	$389 to $1,007 per month
Price detail	Semaglutide price by channel	Dulaglutide price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Ozempic vs Trulicity: which lowers blood sugar more?

Semaglutide, in the direct trial. SUSTAIN 7 compared them dose tier for dose tier in 1,201 adults with type 2 diabetes and found semaglutide lowered HbA1c by 1.5 and 1.8 points versus 1.1 and 1.4 for dulaglutide at 40 weeks. Dulaglutide's higher 3.0 and 4.5 mg doses were approved later and were not in that trial. [1] [3]

Can Trulicity be used for weight loss?

It is not approved for that. Dulaglutide causes modest weight loss in diabetes trials, roughly 3 to 5 kg, while semaglutide 2.4 mg (Wegovy) is approved for chronic weight management with about 15% weight loss in STEP 1. [3] [6] [7]

Which has better heart data?

Both reduce cardiovascular events in type 2 diabetes. Dulaglutide's REWIND trial is the longest (median 5.4 years) and included mostly people without prior cardiovascular disease. Semaglutide has SUSTAIN-6 in diabetes plus SELECT in obesity without diabetes, and only semaglutide carries a cardiovascular indication for people without diabetes. [2] [4] [5] [7]

Is Trulicity easier to use than Ozempic?

Its single-use pen requires no dose dialing and can be injected at any time of day, which some patients prefer. Semaglutide's advantages are an oral option (Rybelsus) and a wider dose range. Both are once weekly injections. [7] [8]

Can children use either?

Dulaglutide is approved for type 2 diabetes in children 10 and older. Semaglutide as Wegovy is approved for weight management in adolescents 12 and older; Ozempic is not labeled for children. [7] [8]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 27). Semaglutide vs dulaglutide: evidence, cost, and legality. https://peptideagent.ai/compare/semaglutide-vs-dulaglutide
HTML link: <a href="https://peptideagent.ai/compare/semaglutide-vs-dulaglutide">Semaglutide vs dulaglutide: evidence, cost, and legality</a>, PeptideAgent, updated September 27, 2026.